| Dr Peter Thomas Pinto, MD | |
|
831 Highway 150 S, Evanston, WY 82930-5340 | |
| (307) 789-3464 | |
| Not Available |
| Full Name | Dr Peter Thomas Pinto |
|---|---|
| Gender | Male |
| Speciality | Psychiatry & Neurology - Psychiatry |
| Location | 831 Highway 150 S, Evanston, Wyoming |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134363195 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 12254A (Wyoming) | Primary |
| Entity Name | The Everett Clinic Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831186766 PECOS PAC ID: 6406752153 Enrollment ID: O20031211000922 |
News Archive
If you think all drugs from Canada are cheaper than U.S. drugs, think again. In the United States, generic drugs - roughly half of all prescriptions - are often cheaper than both Canadian brand-name drugs and Canadian generic drugs, according to a study by the Food and Drug Administration.
The results of the much awaited BEAUTIFUL (morBidity-mortality EvAlUaTion of the If inhibitor ivabradine in patients with CAD and left ventricULar dysfunction) trial have shown that coronary artery disease (CAD) patients with left ventricular dysfunction (LVD) and a heart rate more than 70 bpm have a significantly higher risk of cardiovascular death and other cardiovascular events and in these patients (heart rate above 70 bpm) treatment with ivabradine further reduces the risk of the most important coronary events such as fatal and non-fatal myocardial infarction and coronary revascularisation by one third, even when these patients are already receiving optimal therapy.
Lonza Houston, Inc., a global leader in biological, cell and viral gene therapy manufacturing, and Benitec Biopharma, a clinical stage biotechnology company commercializing a patented gene-silencing technology, DNA-directed RNA interference (ddRNAi), today announced that they have entered into a Manufacturing Services Agreement to develop a scalable manufacturing process for Benitec's ddRNAi-based, Adeno-Associated Virus (AAV)-delivered products intended for therapeutic use in humans.
Mirna Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering microRNA-based Replacement Therapy to treat cancer, today announced the enrollment of the first patient in the hematological malignancy cohort of its ongoing Phase 1 clinical trial of MRX34, the company's lead product candidate and first microRNA mimic in human clinical trials in oncology.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Peter Thomas Pinto, MD 831 Highway 150 S, Evanston, WY 82930-5340 Ph: (307) 789-3464 | Dr Peter Thomas Pinto, MD 831 Highway 150 S, Evanston, WY 82930-5340 Ph: (307) 789-3464 |
News Archive
If you think all drugs from Canada are cheaper than U.S. drugs, think again. In the United States, generic drugs - roughly half of all prescriptions - are often cheaper than both Canadian brand-name drugs and Canadian generic drugs, according to a study by the Food and Drug Administration.
The results of the much awaited BEAUTIFUL (morBidity-mortality EvAlUaTion of the If inhibitor ivabradine in patients with CAD and left ventricULar dysfunction) trial have shown that coronary artery disease (CAD) patients with left ventricular dysfunction (LVD) and a heart rate more than 70 bpm have a significantly higher risk of cardiovascular death and other cardiovascular events and in these patients (heart rate above 70 bpm) treatment with ivabradine further reduces the risk of the most important coronary events such as fatal and non-fatal myocardial infarction and coronary revascularisation by one third, even when these patients are already receiving optimal therapy.
Lonza Houston, Inc., a global leader in biological, cell and viral gene therapy manufacturing, and Benitec Biopharma, a clinical stage biotechnology company commercializing a patented gene-silencing technology, DNA-directed RNA interference (ddRNAi), today announced that they have entered into a Manufacturing Services Agreement to develop a scalable manufacturing process for Benitec's ddRNAi-based, Adeno-Associated Virus (AAV)-delivered products intended for therapeutic use in humans.
Mirna Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering microRNA-based Replacement Therapy to treat cancer, today announced the enrollment of the first patient in the hematological malignancy cohort of its ongoing Phase 1 clinical trial of MRX34, the company's lead product candidate and first microRNA mimic in human clinical trials in oncology.
› Verified 4 days ago
Dr. Robin Regina Ballina, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 325 Front St, #328, Evanston, WY 82930 Phone: 801-319-4726 Fax: 307-789-1283 | |
Dr. Dawn Lynn Stewart, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 831 State Highway 150 S, Evanston, WY 82930 Phone: 307-789-3464 Fax: 307-789-4599 | |
Dr. Patricia A.e. Verellen, M.A., M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 831 State Highway 150 S, Evanston, WY 82930 Phone: 307-789-3464 Fax: 307-789-7373 | |
Dr. Philip Sullivan, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 831 State Highway 150 S, Evanston, WY 82930 Phone: 307-789-3464 Fax: 307-789-7373 | |
Dr. Julie B Maggiolo, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 831 State Highway 150 S, Evanston, WY 82930 Phone: 307-789-3464 Fax: 307-789-7373 |